FUNDAMENTALS · Fundamentals · TW Healthcare

Foresee Pharmaceuticals (6576) Fundamentals 2026 — Revenue Analysis | SniperIQ

Foresee Pharmaceuticals (6576) is a TW-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of NT

3.1B, trading at NT$83.00 on the TWO. This SniperIQ fundamentals page covers Foresee Pharmaceuticals's valuation, profitability (net margin -45.7%), revenue (NT$431M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT
3.1B
Net Margin-45.7%
Revenue (FY25)NT$431M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Foresee Pharmaceuticals's market cap?

Foresee Pharmaceuticals (6576) has a market capitalization of approximately NT

3.1B, trading at NT$83.00 on the TWO. Market cap moves with the live share price.

What is Foresee Pharmaceuticals's P/E ratio?

Foresee Pharmaceuticals's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 9.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Foresee Pharmaceuticals?

Foresee Pharmaceuticals runs a net profit margin of -45.7%, a gross margin of 65.2%, and an operating margin of -177.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Foresee Pharmaceuticals generate?

Foresee Pharmaceuticals reported revenue of NT$431M for fiscal year 2025, with net income of -NT$883M and earnings per share (EPS) of -5.7. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Foresee Pharmaceuticals pay a dividend?

Foresee Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Foresee Pharmaceuticals financially healthy?

Foresee Pharmaceuticals carries a debt-to-equity ratio of 0.29x and a current ratio of 13.61x, with a market beta of 0.59. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Foresee Pharmaceuticals a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Foresee Pharmaceuticals (6576) the key facts are: market cap NT

3.1B, revenue NT$431M, 52-week range 71.9-93.7. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Foresee Pharmaceuticals's full fundamentals live

Get Foresee Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Fresenius Medical Care AG & Co. KGaA (FMS) fundamentals · Elanco Animal Health (ELAN) fundamentals · Nanjing Leads Biolabs (9887) fundamentals · Zhejiang Wolwo Bio-Pharmaceutical (300357) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons